SCHEMBL3401137

SCHEMBL3401137

O=C(Nc1ccc(Cl)nc1)Nc1ccc2nc(N[C@@H]3CCc4ccccc43)ccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
LMNA P02545 1/20 0.40
HPGDS O60760 1/20 0.40
FADS1 O60427 1/20 0.40
CNR1 P21554 1/20 0.39
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
CDK1 P06493 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
CDK5 Q00535 1/20 0.38
MEN1 O00255 3/20 0.38
MAPT P10636 3/20 0.38
KMT2A Q03164 3/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
PFKFB3 Q16875 1/20 0.38
NSD2 O96028 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3398588 0.89 SMARCA2 (0.46) ALDH1A1LMNAHPGDSFADS1CCNE1
SCHEMBL3403165 0.88 KMT2A (0.48) ALDH1A1LMNAHPGDSFADS1MEN1
SCHEMBL3398554 0.87 NPC1 (0.52) ALDH1A1LMNAHPGDSMEN1MAPT
SCHEMBL3405693 0.85 NPC1 (0.45) ALDH1A1LMNAHPGDSCCNE1CDK2
SCHEMBL3411790 0.85 NPC1 (0.42) ALDH1A1LMNAHPGDSFADS1JAK2
SCHEMBL3412407 0.84 JAK2 (0.47) ALDH1A1LMNAHPGDSJAK2JAK1
SCHEMBL3401343 0.83 KMT2A (0.56) ALDH1A1LMNAFADS1MEN1MAPT
SCHEMBL3404447 0.83 MAPT (0.58) ALDH1A1LMNAHPGDSMEN1MAPT
SCHEMBL3415257 0.83 HPGDS (0.46) ALDH1A1LMNAHPGDSFADS1JAK2
SCHEMBL3414984 0.83 AURKA (0.41) HPGDSFADS1JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US claimed
EP-2252372-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-11-24 EP claimed
WO-2009109502-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO claimed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US claimed
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
EP-2252372-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-11-24 EP disclosed
WO-2009109502-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227583-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2B ALDH1A1 2403/4885LMNA 3773/4885HPGDS 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.